A local biotech has secured millions of dollars in new investments to take its RNA therapies for drug-resistant cancers to the clinic.
Gaithersburg’s miRecule Inc. has raised $5.7 million in fresh funding, CEO Anthony Saleh told us Monday, positioning the company to start human testing for its lead candidate to treat head and neck cancer.